Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (Ux143) for the Treatment of Osteogenesis Imperfecta (Oi)
Ultragenyx宣布完成评估Setrusumab(Ux143)治疗成骨不全症(Oi)的第三阶段轨道和宇宙研究的注册
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (Ux143) for the Treatment of Osteogenesis Imperfecta (Oi)
Ultragenyx宣布完成评估Setrusumab(Ux143)治疗成骨不全症(Oi)的第三阶段轨道和宇宙研究的注册
使用浏览器的分享功能,分享给你的好友吧